236 related articles for article (PubMed ID: 16945413)
1. Bortezomib and extramedullary disease in multiple myeloma: the shine and dark side of the moon.
Ali R; Ozkalemkas F; Ozkan A; Ozkocaman V; Ozcelik T; Ozan U; Kurt M; Tunali A
Leuk Res; 2007 Aug; 31(8):1153-5. PubMed ID: 16945413
[No Abstract] [Full Text] [Related]
2. Side effects and good effects from new chemotherapeutic agents. Case 3. Bortezomib in primary refractory plasmacytoma.
Chim CS; Ooi GC; Loong F; Au AW; Lie AK
J Clin Oncol; 2005 Apr; 23(10):2426-8. PubMed ID: 15800336
[No Abstract] [Full Text] [Related]
3. Bortezomib data show improved survival in patients with relapsed multiple myeloma.
Oncology (Williston Park); 2004 Aug; 18(9):1199, 1201. PubMed ID: 15471202
[No Abstract] [Full Text] [Related]
4. Optimizing bortezomib treatment in patients with relapsed multiple myeloma.
Richardson P
Clin Adv Hematol Oncol; 2006 May; 4(5):4-5; discussion 8; suppl 13. PubMed ID: 16832859
[No Abstract] [Full Text] [Related]
5. Hemostatic effects of bortezomib treatment in patients with relapsed or refractory multiple myeloma.
Zangari M; Guerrero J; Cavallo F; Prasad HK; Esseltine D; Fink L
Haematologica; 2008 Jun; 93(6):953-4. PubMed ID: 18515882
[No Abstract] [Full Text] [Related]
6. Bortezomib therapy following first relapse.
Orlowski RZ;
Oncology (Williston Park); 2005 Jan; 19(1):23-6. PubMed ID: 15743149
[No Abstract] [Full Text] [Related]
7. Sustained remission including marked regression of a paravertebral plasmacytoma in a patient with heavily pretreated, relapsed multiple myeloma after treatment with bortezomib.
Krauth MT; Bankier A; Valent P; Kalhs P; Drach J
Leuk Res; 2005 Dec; 29(12):1473-7. PubMed ID: 15964068
[TBL] [Abstract][Full Text] [Related]
8. Inefficacy of bortezomib therapy for CNS involvement of refractory multiple myeloma.
Mele G; Pinna S; Alloro E; Brocca MC; Coppi MR; Quarta G
Leuk Res; 2007 May; 31(5):721-3. PubMed ID: 16890285
[No Abstract] [Full Text] [Related]
9. Bortezomib increases survival of patients with relapsed multiple myeloma.
Health News; 2005 Sep; 11(9):9. PubMed ID: 16211682
[No Abstract] [Full Text] [Related]
10. Effects of bortezomib on bone disease in multiple myeloma.
Drake MT; Rajkumar SV
Am J Hematol; 2009 Jan; 84(1):1-2. PubMed ID: 19030185
[No Abstract] [Full Text] [Related]
11. Bortezomib-based therapy as induction regimen of an autograft program in front-line treatment of multiple myeloma with end-stage renal disease.
Siniscalchi A; Dentamaro T; Perrotti A; Tatangelo P; de Fabritiis P; Caravita T
Ann Hematol; 2010 Aug; 89(8):821-2. PubMed ID: 19953253
[No Abstract] [Full Text] [Related]
12. Successful use of bortezomib in a patient with systemic lupus erythematosus and multiple myeloma.
Fröhlich K; Holle JU; Aries PM; Gross WL; Moosig F
Ann Rheum Dis; 2011 Jul; 70(7):1344-5. PubMed ID: 21173019
[No Abstract] [Full Text] [Related]
13. Use of intrapleural bortezomib in myelomatous pleural effusion.
Iannitto E; Minardi V; Tripodo C
Br J Haematol; 2007 Nov; 139(4):621-2. PubMed ID: 17979947
[No Abstract] [Full Text] [Related]
14. Bortezomib in multiple myeloma.
Mateos MV; San Miguel JF
Best Pract Res Clin Haematol; 2007 Dec; 20(4):701-15. PubMed ID: 18070714
[TBL] [Abstract][Full Text] [Related]
15. Concurrent radiation therapy and bortezomib in myeloma patient.
Berges O; Decaudin D; Servois V; Kirova YM
Radiother Oncol; 2008 Feb; 86(2):290-2. PubMed ID: 18199515
[No Abstract] [Full Text] [Related]
16. Bortezomib in multiple myeloma.
Vandenbroucke JP; Kroep JR
N Engl J Med; 2005 Sep; 353(12):1297-8; author reply 1297-8. PubMed ID: 16180272
[No Abstract] [Full Text] [Related]
17. Approval summary for bortezomib for injection in the treatment of multiple myeloma.
Bross PF; Kane R; Farrell AT; Abraham S; Benson K; Brower ME; Bradley S; Gobburu JV; Goheer A; Lee SL; Leighton J; Liang CY; Lostritto RT; McGuinn WD; Morse DE; Rahman A; Rosario LA; Verbois SL; Williams G; Wang YC; Pazdur R
Clin Cancer Res; 2004 Jun; 10(12 Pt 1):3954-64. PubMed ID: 15217925
[No Abstract] [Full Text] [Related]
18. Efficacy of bortezomib in systemic extramedullary localizations of multiple myeloma.
Federico V; Breccia M; Petrucci MT; Loglisci G; Mansueto G; Mercanti C; Levi A; Cartoni C; Musto P; Alimena G
Clin Adv Hematol Oncol; 2012 Apr; 10(4):266-8. PubMed ID: 22706491
[No Abstract] [Full Text] [Related]
19. Bortezomib, thalidomide, and dexamethasone for relapsed multiple myeloma: add it up and wait.
Badros A; Gahres N
Clin Adv Hematol Oncol; 2005 Dec; 3(12):916-7; discussion 918. PubMed ID: 16555432
[No Abstract] [Full Text] [Related]
20. Three cases of bortezomib-resistant multiple myeloma with extramedullary masses.
Moriuchi M; Ohmachi K; Kojima M; Tsuboi K; Ogawa Y; Nakamura N; Ando K
Tokai J Exp Clin Med; 2010 Apr; 35(1):17-20. PubMed ID: 21319020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]